Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
Authors
Nicolas Villanueva
University of California, San Diego, San Diego, CA
Nicolas Villanueva, Klarissa Son, Shihfan Yeh, Sonia Jain, Elaine Eng, Ken Lloyd, Lan Huang, Ramon W. Mohanlal, Lyudmila Bazhenova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02812667
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS128)
DOI
10.1200/JCO.2019.37.8_suppl.TPS128
Abstract #
TPS128
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2022 ASCO Annual Meeting
Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
First Author: Federico Cappuzzo
Poster
2022 ASCO Annual Meeting
Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.
First Author: Kim Leitzel
Poster
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
First Author: Manuel Rodrigues